Skip to main content
Fig. 4 | Molecular Neurodegeneration

Fig. 4

From: Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay

Fig. 4

Common dementia markers that are significantly elevated in AD compared to LBD. Graphs a-f show the results of the targeted proteomic multiplexed assay of protein biomarkers quantitated in the CSF of control, Lewy body dementia, Parkinson’s and Alzheimer’s disease. Graphs a-f demonstrate the ability of the test to show changes between Lewy Body dementia and Alzheimer’s disease. No significant changes are observed in the PD group.* Denotes new biomarkers not described previously

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326